{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:39:02Z","timestamp":1792561142282,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pierre Fabre"},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme"},{"name":"Takeda"},{"name":"Astellas"},{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Servier"},{"name":"Abbvie"},{"name":"Alexion"},{"name":"Amgen"},{"name":"Johnson & Johnson"},{"name":"Sanofi"},{"name":"Pfizer"},{"name":"Kite\/Gilead"},{"DOI":"10.13039\/100026464","name":"Rochelle Area Community Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026464","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BeOne"},{"name":"AstraZeneca"},{"name":"Eli Lily"},{"name":"Menarini Stemline"},{"name":"Roche"},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neovii"},{"DOI":"10.13039\/100007163","name":"Therakos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) and BRAF\/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified recommendations, and survival outcomes within a prospective cohort of 98 patients with advanced cutaneous or uveal melanoma evaluated by the Molecular Tumor Board Freiburg (MTB-FR) between 2021 and 2024. Completed profiling revealed at least one potential actionable target beyond classical\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600 mutations in 83.8% of cases. Alterations in\n                    <jats:italic>NRAS<\/jats:italic>\n                    , atypical\n                    <jats:italic>BRAF<\/jats:italic>\n                    variants,\n                    <jats:italic>CDK4\/6<\/jats:italic>\n                    pathway amplifications, and DNA-damage response (DDR) gene mutations most frequently guided board recommendations. Biomarker-stratified therapies were recommended for 68.4% of patients, and personalized immunotherapy combinations for 72.4%. The treatment implementation rate was 33.8% (n\u2009=\u200927), achieving an overall disease control rate (DCR) of 42.9% and an overall response rate (ORR) of 10.7%. These findings demonstrate that comprehensive molecular profiling in a real-world setting uncovers actionable alterations, providing viable subsequent treatment avenues that may optimize outcomes for heavily pretreated melanoma patients beyond established standards of care. Ultimately, prospective, randomized, biomarker-driven trials remain essential to validate whether these individualized diagnostic strategies translate into a reproducible survival benefit.\n                  <\/jats:p>","DOI":"10.1038\/s41698-026-01763-w","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:23:06Z","timestamp":1792556586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision oncology in advanced melanoma: molecular landscapes and personalized therapy recommendations from the Molecular Tumor Board Freiburg"],"prefix":"10.1038","volume":"10","author":[{"given":"T.","family":"Lowinus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Schipperges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-1943","authenticated-orcid":false,"given":"P.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Matysiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. P.","family":"Dopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fahrner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5621-0424","authenticated-orcid":false,"given":"A.","family":"Blaumeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6919-4048","authenticated-orcid":false,"given":"H.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-6050","authenticated-orcid":false,"given":"J.","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Falkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bertemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-9984","authenticated-orcid":false,"given":"P.","family":"Bovio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-6821","authenticated-orcid":false,"given":"N.","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cysar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"R.","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gr\u00e4\u00dfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"K.","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"R.","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-3805","authenticated-orcid":false,"given":"C. C.","family":"Miething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-0602","authenticated-orcid":false,"given":"M.","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"F.","family":"Meiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rafei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1002\/cncr.32160","volume":"125","author":"D Pulte","year":"2019","unstructured":"Pulte, D., Weberpals, J., Jansen, L. & Brenner, H. Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. Cancer 125, 2656\u20132665 https:\/\/doi.org\/10.1002\/cncr.32160 (2019).","journal-title":"Cancer"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman, D. C., Green, A. C. & Olsen, C. M. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J. Investig. Dermatol. 136, 1161\u20131171 https:\/\/doi.org\/10.1016\/j.jid.2016.01.035 (2016).","journal-title":"J. Investig. Dermatol."},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158, 495\u2013503 https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160 (2022).","journal-title":"JAMA Dermatol."},{"key":"1763_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 https:\/\/doi.org\/10.1056\/NEJMoa1003466 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1763_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 https:\/\/doi.org\/10.1200\/JCO.21.02229 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1763_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239\u20131251 https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2 (2019).","journal-title":"Lancet Oncol."},{"key":"1763_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.20517\/cdr.2019.28","volume":"2","author":"SE Fenton","year":"2019","unstructured":"Fenton, S. E., Sosman, J. A. & Chandra, S. Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. Cancer Drug Resist. 2, 744\u2013761 https:\/\/doi.org\/10.20517\/cdr.2019.28 (2019).","journal-title":"Cancer Drug Resist."},{"key":"1763_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 https:\/\/doi.org\/10.1056\/NEJMoa1604958 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1763_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 https:\/\/doi.org\/10.1016\/j.ccell.2020.03.017 (2020).","journal-title":"Cancer Cell"},{"key":"1763_CR10","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1541-7786.MCR-22-0898","volume":"21","author":"M Langenbach","year":"2023","unstructured":"Langenbach, M. et al. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL15 and MHC Class II production. Mol. Cancer Res. 21, 849\u2013864 https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0898 (2023).","journal-title":"Mol. Cancer Res."},{"key":"1763_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 https:\/\/doi.org\/10.1016\/j.cell.2017.01.017 (2017).","journal-title":"Cell"},{"key":"1763_CR12","doi-asserted-by":"publisher","first-page":"e014564","DOI":"10.1136\/jitc-2025-014564","volume":"14","author":"EM Gaughan","year":"2026","unstructured":"Gaughan, E. M. et al. Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study. J. Immunother. Cancer 14, e014564 https:\/\/doi.org\/10.1136\/jitc-2025-014564 (2026).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis, K. et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat. Cancer 6, 924\u2013937 https:\/\/doi.org\/10.1038\/s43018-025-00986-3 (2025).","journal-title":"Nat. Cancer"},{"key":"1763_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 https:\/\/doi.org\/10.1038\/s41577-019-0218-4 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1763_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely, M. D., Zhang, T. & Chen, L. Resistance mechanisms to Anti-PD cancer immunotherapy. Annu Rev. Immunol. 40, 45\u201374 https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155 (2022).","journal-title":"Annu Rev. Immunol."},{"key":"1763_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151\u2013167 https:\/\/doi.org\/10.1038\/s41571-018-0142-8 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1763_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139\u2013147 https:\/\/doi.org\/10.1038\/nrc.2017.117 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1763_CR18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1158\/2159-8290.CD-25-1745","volume":"16","author":"KM Campbell","year":"2026","unstructured":"Campbell, K. M. et al. Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1. Cancer Discov. 16, 1801\u20131818 https:\/\/doi.org\/10.1158\/2159-8290.CD-25-1745 (2026).","journal-title":"Cancer Discov."},{"key":"1763_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/cancers17091422","volume":"17","author":"IL Szabo","year":"2025","unstructured":"Szabo, I. L., Emri, G., Ladanyi, A. & Timar, J. Clinical applications of the molecular landscape of melanoma: integration of research into diagnostic and therapeutic strategies. Cancers 17, 1422 https:\/\/doi.org\/10.3390\/cancers17091422 (2025).","journal-title":"Cancers"},{"key":"1763_CR20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877\u20131888 https:\/\/doi.org\/10.1056\/NEJMoa1406037 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1763_CR21","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","volume":"51","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B. et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer 51, 2792\u20132799 https:\/\/doi.org\/10.1016\/j.ejca.2015.08.022 (2015).","journal-title":"Eur. J. Cancer"},{"key":"1763_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2017.06.09","volume":"5","author":"I Arozarena","year":"2017","unstructured":"Arozarena, I. & Wellbrock, C. Overcoming resistance to BRAF inhibitors. Ann. Transl. Med. 5, 387 https:\/\/doi.org\/10.21037\/atm.2017.06.09 (2017).","journal-title":"Ann. Transl. Med."},{"key":"1763_CR23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/ph18081235","volume":"18","author":"I Cosci","year":"2025","unstructured":"Cosci, I. et al. Molecular basis of BRAF inhibitor resistance in melanoma: a systematic review. Pharmaceuticals 18, 1235 https:\/\/doi.org\/10.3390\/ph18081235 (2025).","journal-title":"Pharmaceuticals"},{"key":"1763_CR24","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","volume":"19","author":"KE Hutchinson","year":"2013","unstructured":"Hutchinson, K. E. et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin. Cancer Res. 19, 6696\u20136702 https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1746 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1763_CR25","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41591-023-02304-9","volume":"29","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. Multi-organ landscape of therapy-resistant melanoma. Nat. Med. 29, 1123\u20131134 https:\/\/doi.org\/10.1038\/s41591-023-02304-9 (2023).","journal-title":"Nat. Med."},{"key":"1763_CR26","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.3390\/cancers15123224","volume":"15","author":"MF Fernandez","year":"2023","unstructured":"Fernandez, M. F., Choi, J. & Sosman, J. New approaches to targeted therapy in melanoma. Cancers 15, 3224 https:\/\/doi.org\/10.3390\/cancers15123224 (2023).","journal-title":"Cancers"},{"key":"1763_CR27","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.18632\/oncotarget.3655","volume":"6","author":"H Cirenajwis","year":"2015","unstructured":"Cirenajwis, H. et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 6, 12297\u201312309 https:\/\/doi.org\/10.18632\/oncotarget.3655 (2015).","journal-title":"Oncotarget"},{"key":"1763_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15606-0","volume":"11","author":"J Karlsson","year":"2020","unstructured":"Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 https:\/\/doi.org\/10.1038\/s41467-020-15606-0 (2020).","journal-title":"Nat. Commun."},{"key":"1763_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abk1692","volume":"7","author":"T Hoch","year":"2022","unstructured":"Hoch, T. et al. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci. Immunol. 7, eabk1692 https:\/\/doi.org\/10.1126\/sciimmunol.abk1692 (2022).","journal-title":"Sci. Immunol."},{"key":"1763_CR30","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/cells10092320","volume":"10","author":"C Teixido","year":"2021","unstructured":"Teixido, C., Castillo, P., Martinez-Vila, C., Arance, A. & Alos, L. Molecular markers and targets in melanoma. Cells 10, 2320 https:\/\/doi.org\/10.3390\/cells10092320 (2021).","journal-title":"Cells"},{"key":"1763_CR31","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41591-025-03715-6","volume":"31","author":"N Miglino","year":"2025","unstructured":"Miglino, N. et al. Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nat. Med. 31, 2430\u20132441 https:\/\/doi.org\/10.1038\/s41591-025-03715-6 (2025).","journal-title":"Nat. Med."},{"key":"1763_CR32","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-021-00243-3","volume":"2","author":"B Reardon","year":"2021","unstructured":"Reardon, B. et al. Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. Nat. Cancer 2, 1102\u20131112 https:\/\/doi.org\/10.1038\/s43018-021-00243-3 (2021).","journal-title":"Nat. Cancer"},{"key":"1763_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard, C. et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 7, 586\u2013595 https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1396 (2017).","journal-title":"Cancer Discov."},{"key":"1763_CR34","doi-asserted-by":"publisher","unstructured":"Hoefflin, R. et al. Personalized clinical decision making through implementation of a molecular tumor board: a German single-center experience. JCO Precis. Oncol. 2 https:\/\/doi.org\/10.1200\/PO.18.00105 (2018).","DOI":"10.1200\/PO.18.00105"},{"key":"1763_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/cancers13051151","volume":"13","author":"R Hoefflin","year":"2021","unstructured":"Hoefflin, R. et al. Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis. Cancers 13, 1151 https:\/\/doi.org\/10.3390\/cancers13051151 (2021).","journal-title":"Cancers"},{"key":"1763_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung, E. Z. & Gershenwald, J. E. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev. Anticancer Ther. 18, 775\u2013784 https:\/\/doi.org\/10.1080\/14737140.2018.1489246 (2018).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1763_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.jidsp.5640173","volume":"4","author":"NM Wikonkal","year":"1999","unstructured":"Wikonkal, N. M. & Brash, D. E. Ultraviolet radiation induced signature mutations in photocarcinogenesis. J. Investig. Dermatol Symp. Proc. 4, 6\u201310 https:\/\/doi.org\/10.1038\/sj.jidsp.5640173 (1999).","journal-title":"J. Investig. Dermatol Symp. Proc."},{"key":"1763_CR38","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/jid.2008.165","volume":"128","author":"TM Runger","year":"2008","unstructured":"Runger, T. M. C\u2192 T transition mutations are not solely UVB-signature mutations, because they are also generated by UVA. J. Investig. Dermatol 128, 2138\u20132140 https:\/\/doi.org\/10.1038\/jid.2008.165 (2008).","journal-title":"J. Investig. Dermatol"},{"key":"1763_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3389\/fimmu.2019.01113","volume":"10","author":"H Chen","year":"2019","unstructured":"Chen, H. et al. Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades. Front. Immunol. 10, 1113 https:\/\/doi.org\/10.3389\/fimmu.2019.01113 (2019).","journal-title":"Front. Immunol."},{"key":"1763_CR40","doi-asserted-by":"publisher","first-page":"e001792","DOI":"10.1136\/jitc-2020-001792","volume":"9","author":"LC Brown","year":"2021","unstructured":"Brown, L. C. et al. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J. Immunother. Cancer 9, e001792 https:\/\/doi.org\/10.1136\/jitc-2020-001792 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR41","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis, N. M. et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am. J. Hum. Genet. 99, 877\u2013885 https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.016 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"1763_CR42","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-25-0952","volume":"31","author":"AJ Armstrong","year":"2025","unstructured":"Armstrong, A. J. et al. LRP1b loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the Phase III CheckMate-026 randomized trial. Clin. Cancer Res. 31, 5198\u20135210 https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-0952 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1763_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1535370220959657","volume":"246","author":"J Owsley","year":"2021","unstructured":"Owsley, J. et al. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp. Biol. Med. 246, 31\u201339 https:\/\/doi.org\/10.1177\/1535370220959657 (2021).","journal-title":"Exp. Biol. Med."},{"key":"1763_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5864-1","volume":"19","author":"PM Lokhandwala","year":"2019","unstructured":"Lokhandwala, P. M. et al. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer 19, 665 https:\/\/doi.org\/10.1186\/s12885-019-5864-1 (2019).","journal-title":"BMC Cancer"},{"key":"1763_CR45","doi-asserted-by":"publisher","first-page":"77163","DOI":"10.18632\/oncotarget.12848","volume":"7","author":"MI Raaijmakers","year":"2016","unstructured":"Raaijmakers, M. I. et al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget 7, 77163\u201377174 https:\/\/doi.org\/10.18632\/oncotarget.12848 (2016).","journal-title":"Oncotarget"},{"key":"1763_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/ol.2022.13613","volume":"25","author":"T Zablocka","year":"2023","unstructured":"Zablocka, T., Kreismane, M., Pjanova, D. & Isajevs, S. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncol. Lett. 25, 27 https:\/\/doi.org\/10.3892\/ol.2022.13613 (2023).","journal-title":"Oncol. Lett."},{"key":"1763_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 https:\/\/doi.org\/10.1038\/nature09626 (2010).","journal-title":"Nature"},{"key":"1763_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/CMR.0000000000000808","volume":"32","author":"MJ Hotz","year":"2022","unstructured":"Hotz, M. J. et al. Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma. Melanoma Res. 32, 112\u2013119 https:\/\/doi.org\/10.1097\/CMR.0000000000000808 (2022).","journal-title":"Melanoma Res."},{"key":"1763_CR49","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner, A. et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J. Immunother. Cancer 7, 180 https:\/\/doi.org\/10.1186\/s40425-019-0659-0 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR50","doi-asserted-by":"publisher","first-page":"e001501","DOI":"10.1136\/jitc-2020-001501","volume":"8","author":"EP Hoefsmit","year":"2020","unstructured":"Hoefsmit, E. P. et al. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J. Immunother. Cancer 8, e001501 https:\/\/doi.org\/10.1136\/jitc-2020-001501 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74956-3","volume":"10","author":"LG Aoude","year":"2020","unstructured":"Aoude, L. G. et al. Pathogenic germline variants are associated with poor survival in stage III\/IV melanoma patients. Sci. Rep. 10, 17687 https:\/\/doi.org\/10.1038\/s41598-020-74956-3 (2020).","journal-title":"Sci. Rep."},{"key":"1763_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00292-025-01441-x","volume":"46","author":"EP Dopfer","year":"2025","unstructured":"Dopfer, E. P. et al. [Trop-2 expression in solid tumors: expanded protein diagnostics within the molecular tumor board]. Pathologie 46, 301\u2013307 https:\/\/doi.org\/10.1007\/s00292-025-01441-x (2025).","journal-title":"Pathologie"},{"key":"1763_CR53","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cels.2017.08.013","volume":"5","author":"E Goncalves","year":"2017","unstructured":"Goncalves, E. et al. Widespread post-transcriptional attenuation of genomic copy-number variation in cancer. Cell Syst. 5, 386\u2013398.e4 https:\/\/doi.org\/10.1016\/j.cels.2017.08.013 (2017).","journal-title":"Cell Syst."},{"key":"1763_CR54","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jid.2023.12.011","volume":"144","author":"S Naimy","year":"2024","unstructured":"Naimy, S. et al. Comparative quantitative proteomic analysis of melanoma subtypes, nevus-associated melanoma, and corresponding nevi. J. Investig. Dermatol 144, 1608\u20131621.e4 https:\/\/doi.org\/10.1016\/j.jid.2023.12.011 (2024).","journal-title":"J. Investig. Dermatol"},{"key":"1763_CR55","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2025.43.16_suppl.3119","volume":"43","author":"AL Illert","year":"2025","unstructured":"Illert, A. L. et al. Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial). J. Clin. Oncol. 43, 3119\u20133119 https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3119 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1763_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00458-w","volume":"7","author":"A Mock","year":"2023","unstructured":"Mock, A. et al. NCT\/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. npj Precis. Oncol. 7, 109 https:\/\/doi.org\/10.1038\/s41698-023-00458-w (2023).","journal-title":"npj Precis. Oncol."},{"key":"1763_CR57","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ijc.30828","volume":"141","author":"P Horak","year":"2017","unstructured":"Horak, P. et al. Precision oncology based on omics data: The NCT Heidelberg experience. Int J. Cancer 141, 877\u2013886 https:\/\/doi.org\/10.1002\/ijc.30828 (2017).","journal-title":"Int J. Cancer"},{"key":"1763_CR58","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 https:\/\/doi.org\/10.1093\/annonc\/mdy263 (2018).","journal-title":"Ann. Oncol."},{"key":"1763_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.22.00221","volume":"41","author":"A Arance","year":"2023","unstructured":"Arance, A. et al. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination. J. Clin. Oncol. 41, 75\u201385 https:\/\/doi.org\/10.1200\/JCO.22.00221 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1763_CR60","doi-asserted-by":"publisher","first-page":"e006821","DOI":"10.1136\/jitc-2023-006821","volume":"11","author":"EA Rozeman","year":"2023","unstructured":"Rozeman, E. A. et al. IMPemBra: a phase 2 study comparing pembrolizumab with intermittent\/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation. J. Immunother. Cancer 11, e006821 https:\/\/doi.org\/10.1136\/jitc-2023-006821 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR61","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci, P. F. et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J. Immunother. Cancer 8, e001806 https:\/\/doi.org\/10.1136\/jitc-2020-001806 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1763_CR62","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter, J. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390, 1853\u20131862 https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X (2017).","journal-title":"Lancet"},{"key":"1763_CR63","doi-asserted-by":"publisher","first-page":"e8404","DOI":"10.1097\/MD.0000000000008404","volume":"96","author":"EJ Hannan","year":"2017","unstructured":"Hannan, E. J. et al. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: the implications for BRAF inhibitor therapy. Medicine 96, e8404 https:\/\/doi.org\/10.1097\/MD.0000000000008404 (2017).","journal-title":"Medicine"},{"key":"1763_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1515-3","volume":"15","author":"Z Helias-Rodzewicz","year":"2015","unstructured":"Helias-Rodzewicz, Z. et al. Variations of BRAF mutant allele percentage in melanomas. BMC Cancer 15, 497 https:\/\/doi.org\/10.1186\/s12885-015-1515-3 (2015).","journal-title":"BMC Cancer"},{"key":"1763_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.2016.008912","volume":"4","author":"E Ruiz-Garcia","year":"2018","unstructured":"Ruiz-Garcia, E. et al. Frequency of BRAF V600E mutation in the mexican population of patients with metastatic melanoma. J. Glob. Oncol. 4, 1\u20135 https:\/\/doi.org\/10.1200\/JGO.2016.008912 (2018).","journal-title":"J. Glob. Oncol."},{"key":"1763_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.12788\/cutis.0515","volume":"109","author":"JA Harvey","year":"2022","unstructured":"Harvey, J. A. et al. BRAF V600E expression in primary melanoma and its association with death: a population-based, retrospective, cross-sectional study. Cutis 109, 279\u2013283 https:\/\/doi.org\/10.12788\/cutis.0515 (2022).","journal-title":"Cutis"},{"key":"1763_CR67","doi-asserted-by":"publisher","unstructured":"Can, N. et al. BRAF V600 mutation profile of metastatic melanoma in the Thrace Region of Turkey. Turk Patoloji Derg. https:\/\/doi.org\/10.5146\/tjpath.2018.01422 (2018).","DOI":"10.5146\/tjpath.2018.01422"},{"key":"1763_CR68","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies, M. A. et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117, 1687\u20131696 https:\/\/doi.org\/10.1002\/cncr.25634 (2011).","journal-title":"Cancer"},{"key":"1763_CR69","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","volume":"19","author":"DN Cagney","year":"2017","unstructured":"Cagney, D. N. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 19, 1511\u20131521 https:\/\/doi.org\/10.1093\/neuonc\/nox077 (2017).","journal-title":"Neuro Oncol."},{"key":"1763_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115253","volume":"217","author":"S Pedersen","year":"2025","unstructured":"Pedersen, S. et al. Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: insights from a nationwide study (2015-2022). Eur. J. Cancer 217, 115253 https:\/\/doi.org\/10.1016\/j.ejca.2025.115253 (2025).","journal-title":"Eur. J. Cancer"},{"key":"1763_CR71","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/ijms22020976","volume":"22","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y., Murata, M., Shen, C. H., Furue, M. & Ito, T. NECTIN4: a novel therapeutic target for melanoma. Int. J. Mol. Sci. 22, 976 https:\/\/doi.org\/10.3390\/ijms22020976 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1763_CR72","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/fon-2020-0163","volume":"16","author":"HS Rugo","year":"2020","unstructured":"Rugo, H. S. et al. TROPiCS-02: a Phase III study investigating sacituzumab govitecan in the treatment of HR+\/HER2- metastatic breast cancer. Future Oncol. 16, 705\u2013715 https:\/\/doi.org\/10.2217\/fon-2020-0163 (2020).","journal-title":"Future Oncol."},{"key":"1763_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113976","volume":"202","author":"LJ Albrecht","year":"2024","unstructured":"Albrecht, L. J. et al. Anti-PD-(L)1 plus BRAF\/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. Eur. J. Cancer 202, 113976 https:\/\/doi.org\/10.1016\/j.ejca.2024.113976 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1763_CR74","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20199111","volume":"16","author":"T Muller","year":"2020","unstructured":"Muller, T. et al. Automated sample preparation with SP3 for low-input clinical proteomics. Mol. Syst. Biol. 16, e9111 https:\/\/doi.org\/10.15252\/msb.20199111 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"1763_CR75","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.2","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett, S. W. & Andrews, S. FastQ Screen: a tool for multi-genome mapping and quality control. F1000Research 7, 1338 https:\/\/doi.org\/10.12688\/f1000research.15931.2 (2018).","journal-title":"F1000Research"},{"key":"1763_CR76","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 https:\/\/doi.org\/10.1093\/bioinformatics\/btu170 (2014).","journal-title":"Bioinformatics"},{"key":"1763_CR77","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 https:\/\/doi.org\/10.1101\/gr.107524.110 (2010).","journal-title":"Genome Res."},{"key":"1763_CR78","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 https:\/\/doi.org\/10.1101\/gr.129684.111 (2012).","journal-title":"Genome Res."},{"key":"1763_CR79","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 https:\/\/doi.org\/10.1038\/ng.806 (2011).","journal-title":"Nat. Genet."},{"key":"1763_CR80","doi-asserted-by":"publisher","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform. 43, 11.10.1\u201311.10.33 https:\/\/doi.org\/10.1002\/0471250953.bi1110s43 (2013).","DOI":"10.1002\/0471250953.bi1110s43"},{"key":"1763_CR81","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443 https:\/\/doi.org\/10.1038\/s41586-020-2308-7 (2020).","journal-title":"Nature"},{"key":"1763_CR82","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017 https:\/\/doi.org\/10.1200\/PO.17.00011 (2017).","DOI":"10.1200\/PO.17.00011"},{"key":"1763_CR83","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862\u2013D868 https:\/\/doi.org\/10.1093\/nar\/gkv1222 (2016).","journal-title":"Nucleic Acids Res."},{"key":"1763_CR84","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 https:\/\/doi.org\/10.1093\/nar\/gkx1153 (2018).","journal-title":"Nucleic Acids Res."},{"key":"1763_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","volume":"100","author":"Q Li","year":"2017","unstructured":"Li, Q. & Wang, K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am. J. Hum. Genet. 100, 267\u2013280 https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.004 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1763_CR86","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 8, 174\u2013183 https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0321 (2018).","journal-title":"Cancer Discov."},{"key":"1763_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155\u2013163 https:\/\/doi.org\/10.1038\/nbt.3391 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1763_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00803-9","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 12, 103 https:\/\/doi.org\/10.1186\/s13073-020-00803-9 (2020).","journal-title":"Genome Med."},{"key":"1763_CR89","doi-asserted-by":"publisher","unstructured":"Nicorici, D. et al. FusionCatcher\u2014a tool for finding somatic fusion genes in paired-end RNA-sequencing data. Preprint at https:\/\/doi.org\/10.1101\/011650 (2014).","DOI":"10.1101\/011650"},{"key":"1763_CR90","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gr.257246.119","volume":"31","author":"S Uhrig","year":"2021","unstructured":"Uhrig, S. et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 31, 448\u2013460 https:\/\/doi.org\/10.1101\/gr.257246.119 (2021).","journal-title":"Genome Res."},{"key":"1763_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-10-r80","volume":"5","author":"RC Gentleman","year":"2004","unstructured":"Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 https:\/\/doi.org\/10.1186\/gb-2004-5-10-r80 (2004).","journal-title":"Genome Biol."},{"key":"1763_CR92","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 https:\/\/doi.org\/10.1101\/gr.239244.118 (2018).","journal-title":"Genome Res."},{"key":"1763_CR93","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: a 2D graphics environment. Comput. Sci. Eng. 9, 90\u201395 https:\/\/doi.org\/10.1109\/MCSE.2007.55 (2007).","journal-title":"Comput. Sci. Eng."},{"key":"1763_CR94","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/cancers15133456","volume":"15","author":"P Metzger","year":"2023","unstructured":"Metzger, P. et al. MIRACUM-Pipe: an adaptable pipeline for next-generation sequencing analysis, reporting, and visualization for clinical decision making. Cancers 15, 3456 https:\/\/doi.org\/10.3390\/cancers15133456 (2023).","journal-title":"Cancers"},{"key":"1763_CR95","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1055\/s-0042-1743560","volume":"13","author":"P Unberath","year":"2022","unstructured":"Unberath, P. et al. Searching of clinical trials made easier in cBioPortal using patients\u2019 genetic and clinical profiles. Appl. Clin. Inform. 13, 363\u2013369 https:\/\/doi.org\/10.1055\/s-0042-1743560 (2022).","journal-title":"Appl. Clin. Inform."},{"key":"1763_CR96","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/diagnostics10020093","volume":"10","author":"P Buechner","year":"2020","unstructured":"Buechner, P. et al. Requirements analysis and specification for a molecular tumor board platform based on cBioPortal. Diagnostics 10, 93 https:\/\/doi.org\/10.3390\/diagnostics10020093 (2020).","journal-title":"Diagnostics"},{"key":"1763_CR97","doi-asserted-by":"publisher","first-page":"e50017","DOI":"10.2196\/50017","volume":"11","author":"C Renner","year":"2023","unstructured":"Renner, C. et al. Extending cBioPortal for therapy recommendation documentation in molecular tumor boards: development and usability study. JMIR Med. Informatics. 11, e50017 https:\/\/doi.org\/10.2196\/50017 (2023).","journal-title":"JMIR Med. Informatics."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01763-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:46:37Z","timestamp":1792557997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01763-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01763-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.R. served as a consultant and\/or has received honoraria from Almirall and Bristol-Myers Squibb and travel support from Sun Pharma and Pierre Fabre. F.M. served as consultant and\/or has received honoraria from Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Sanofi Genzyme, Sun Pharma and travel support from Novartis, Sun Pharma, Pierre Fabre and Merck Sharp & Dohme. R.Z. received honoraria from Novartis, Incyte, Sanofi, Medac, Neovii and Therakos. T.B. received speaker honoraria from the European Society for Medical Oncology (ESMO) and Pierre Fabre. Si.La. reports a research grant from BMS and advisory board\/speaker invitation from AstraZeneca, Eli Lilly, Menarini Stemline, Roche, and Takeda. Hei.Bec. received honoraria from Astellas, BMS, GSK, MSD, Novartis, Servier, and Takeda. R.W. consulted for and\/or received honoraria from AbbVie, Alexion, Amgen, BMS, Johnson & Johnson, Kite\/Gilead, Novartis, Pfizer, Sanofi, and Takeda, and received research funding from Johnson & Johnson and Sanofi, all paid to UKF. L.G. received honoraria from Roche and travel support from BeOne. All competing interests are outside the submitted work. The other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"400"}}